Megan Jones - EXACT Sciences Associate Relations
| EXAS Stock | USD 47.76 0.81 1.73% |
Insider
Megan Jones is Associate Relations of EXACT Sciences
| Address | 5505 Endeavor Lane, Madison, WI, United States, 53719 |
| Phone | 608 284 5700 |
| Web | https://www.exactsciences.com |
EXACT Sciences Management Efficiency
The company has return on total asset (ROA) of (0.0183) % which means that it has lost $0.0183 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3689) %, meaning that it created substantial loss on money invested by shareholders. EXACT Sciences' management efficiency ratios could be used to measure how well EXACT Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.42 in 2025. Return On Capital Employed is likely to drop to -0.21 in 2025. At this time, EXACT Sciences' Intangibles To Total Assets are comparatively stable compared to the past year. Debt To Assets is likely to gain to 0.49 in 2025, whereas Return On Tangible Assets are likely to drop (0.42) in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| LLM LLM | Natera Inc | 55 | |
| Natalie Welch | Pacific Biosciences of | N/A | |
| Jonathan MEng | Natera Inc | 52 | |
| Eric Evans | Natera Inc | N/A | |
| Mark Oene | Pacific Biosciences of | 52 | |
| Michele CPA | Pacific Biosciences of | 45 | |
| Emmanuelle Charpentier | Crispr Therapeutics AG | N/A | |
| Trevin Rard | Pacific Biosciences of | N/A | |
| Lawrence Klein | Crispr Therapeutics AG | 42 | |
| Rachel Haurwitz | Intellia Therapeutics | 39 | |
| Aaron Sato | Twist Bioscience Corp | N/A | |
| Andrew May | Intellia Therapeutics | N/A | |
| Matthew MD | Crispr Therapeutics AG | 60 | |
| Susan Tousi | Illumina | 55 | |
| Chad Cowan | Crispr Therapeutics AG | 53 | |
| Carissa Rollins | Illumina | 55 | |
| Scott Ericksen | Illumina | 52 | |
| Olesya CPA | Natera Inc | N/A | |
| Brendan MBA | Crispr Therapeutics AG | 48 | |
| Darya Chudova | Guardant Health | 51 | |
| Michael Bell | Guardant Health | 56 | |
Management Performance
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.0183 |
EXACT Sciences Leadership Team
Elected by the shareholders, the EXACT Sciences' board of directors comprises two types of representatives: EXACT Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EXACT. The board's role is to monitor EXACT Sciences' management team and ensure that shareholders' interests are well served. EXACT Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EXACT Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Conroy, Chairman of The Board, CEO and Pres | ||
| Ana Hooker, Chief Officer | ||
| Aaron Bloomer, Executive Finance | ||
| Vic Parker, Head Sales | ||
| Sri Kalluri, Chief Officer | ||
| Nassar Nizami, Chief Officer | ||
| Scott Coward, Sr. VP and General Counsel | ||
| Jake MBA, Executive Screening | ||
| Graham Lidgard, Chief Science Officer and Sr. VP | ||
| Jorge Garces, Chief Officer | ||
| Jeffrey CFA, Chief Officer | ||
| Erik Holznecht, Senior Associate | ||
| Derek Leckow, Vice Relations | ||
| James Herriott, General VP | ||
| Jacob MBA, Executive Screening | ||
| Steven Bellamy, Chief Region | ||
| Sarah Condella, Executive Resources | ||
| Tim Caprez, Chief VP | ||
| Brian Baranick, Executive Oncology | ||
| Vamsi Pudipeddi, Chief Officer | ||
| Everett Cunningham, Chief Officer | ||
| Frederick MD, Chief Oncology | ||
| Wayne Taylor, Head VP | ||
| Nicole Maassen, Market President | ||
| Kevin JD, Chairman CEO | ||
| MD FACP, Chief Detection | ||
| Megan Jones, Associate Relations | ||
| MPH MD, Chief Screening |
EXACT Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EXACT Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.0183 | ||||
| Profit Margin | (0.36) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 10.6 B | ||||
| Shares Outstanding | 188.64 M | ||||
| Shares Owned By Insiders | 0.92 % | ||||
| Shares Owned By Institutions | 99.08 % | ||||
| Number Of Shares Shorted | 7.47 M | ||||
| Price To Earning | (38.17) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for EXACT Stock Analysis
When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.